There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
To evaluate the short-term efficacy of (l)-2-oxothiaolidine-4-carboxylate (OTZ, which
reduces urinary oxalate excretion in normal subjects) in the treatment of primary
hyperoxaluria type 1 (PH1) in a phase II study.